FSCN1抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P00177(FSCN1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P00177(FSCN1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Fascin-1 (FSCN1) is an actin-bundling protein encoded by the *FSCN1* gene, primarily involved in organizing cytoskeletal structures such as filopodia, lamellipodia, and invadopodia. These dynamic membrane protrusions are critical for cell migration, adhesion, and invasion, making FSCN1 a key player in physiological processes like immune response and tissue repair, as well as pathological conditions, particularly cancer metastasis. Overexpression of FSCN1 is frequently observed in aggressive carcinomas (e.g., breast, colorectal, and lung cancers) and correlates with poor prognosis, suggesting its role as a biomarker for tumor progression.

FSCN1 antibodies are immunological tools designed to detect and quantify Fascin-1 protein levels in research and clinical settings. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study Fascin-1's expression patterns, subcellular localization, and functional interactions. These antibodies help elucidate mechanisms underlying cancer cell invasion, epithelial-mesenchymal transition (EMT), and resistance to therapies. Commercially available FSCN1 antibodies include monoclonal and polyclonal variants, often validated for specificity across human, mouse, and rat samples. Recent studies also explore FSCN1 as a potential therapeutic target, with inhibitors under investigation to disrupt its actin-binding activity and impede metastatic behavior. However, challenges remain in ensuring antibody cross-reactivity and reproducibility across experimental models.